(E)-2-styrylchromone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (E)-2-styrylchromone
• 英文别名: (E)-2-styryl-4H-chromen-4-one；2-[(1E)-2-phenylethenyl]-4H-1-benzopyran-4-one；2-[(E)-2-phenylethenyl]chromen-4-one
• 化学式: C₁₇H₁₂O₂
• 分子量: 248.281
• InChiKey: LSTAHPMLLDYWKN-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-2-styrylchromone 在 盐酸 作用下， 以 溶剂黄146 为溶剂， 反应 5.0h， 生成 trans-3-acetoxymethyl-2-styrylchromen-4-one
  参考文献：
  名称：

  Buggy, Thomas; Ellis, Gwynn P., Journal of Chemical Research, Miniprint, 1980, # 5, p. 2314 - 2324

  摘要：

  DOI：
• 作为产物：
  描述：

  桂皮[酸]酐 在 barium dihydroxide 、 对甲苯磺酸 作用下， 以 二甲基亚砜 、 丙酮 为溶剂， 反应 0.03h， 生成 (E)-2-styrylchromone
  参考文献：
  名称：

  Goel, Sharda; Ritu; Makrandi, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 5, p. 1278 - 1281

  摘要：

  DOI：

文献信息

• New Route to Styrylchromones via [1-(2-Hydroxybenzoyl)alkylidene]triphenylphosphoranes
  作者：F. Zammattio、J. D. Brion、P. Ducrey、G. Le Baut

  DOI：10.1055/s-1992-26115

  日期：——

  Several [1-(2-hydroxybenzoyl)alkylidene]triphenylphosphoranes have been obtained in good yields through acylation of the corresponding alkylidenetriphenylphosphoranes, prepared in situ, by the easily available methyl 2-hydroxybenzoates. These ylides proved to be good starting materials for the synthesis of the corresponding 2-styrylchromones (2-styryl-4H-1-benzopyran-4-ones).

  已通过将相应的亚烷基三苯膦（当场制备）与易获得的2-羟基苯甲酸甲酯进行酰化反应，获得了产率良好的数种[1-(2-羟基苯甲酰基)亚烷基]三苯膦。这些叶立德已被证实是合成相应2-苯乙烯基色酮（2-苯乙烯基-4H-1-苯并吡喃-4-酮）的良好起始材料。
• Synthesis and evaluation of antioxidant activity of 2-styrylchromones
  作者：Shrinivas P. Pawar、Dasharath D. Kondhare、P. K. Zubaidha

  DOI：10.1007/s00044-012-0069-z

  日期：2013.2

  oestrogenic and antibacterial activities, in particular the antioxidant behavior of these compounds continue to draw attention of researchers. In the present communication a series of halo substituted 2-styrylchromones 4a–4k were prepared and tested for the antioxidant activity by using DPPH (1, 1 diphenyl 2, picryl hydrazyl) method, and among the synthesized compounds 4e and 4h shows strong antioxidant activity

  抗氧化剂正在作为潜在的预防和治疗剂出现，它们可以清除自由基，否则会破坏活性氧并防止其引起的损害。自由基与多种疾病的发病机理有关，如癌症，糖尿病，心血管疾病，自身免疫疾病，神经退行性疾病，并与衰老有关。色酮及其衍生物具有重要的生物学活性，例如抗肿瘤，抗肝毒，抗炎，抗痉挛，雌激素和抗菌活性，特别是这些化合物的抗氧化性能继续引起研究人员的注意。在本来文中，一系列卤素取代的2-苯乙烯基色酮4a – 4k制备并通过DPPH（1，1，二苯基2，吡啶基肼基）方法测试抗氧化剂的活性，在合成的化合物4e和4h中显示出强的抗氧化剂活性，而其余化合物在正常范围内显示出抗氧化剂活性。
• Exploration of synthetic antioxidant flavonoid analogs as acetylcholinesterase inhibitors: an approach towards finding their quantitative structure–activity relationship
  作者：Abhijit Karmakar、Pravin Ambure、Tamanna Mallick、Sreeparna Das、Kunal Roy、Naznin Ara Begum

  DOI：10.1007/s00044-019-02330-8

  日期：2019.5

  acetylcholinesterase (AChE) and a series of antioxidant flavonoid analogs were studied by fluorescence spectroscopic assay. The present study incorporated different classes of naturally occurring and synthetic flavonoid compounds like flavones, isoflavones, and chalcones as well as a few standard antioxidants. The AChE inhibitory (AChEI) activity of these compounds was further analyzed using in silico techniques

  通过荧光光谱法研究了乙酰胆碱酯酶（AChE）与一系列抗氧化剂类黄酮类似物之间的结合相互作用。本研究纳入了不同种类的天然和合成类黄酮化合物，例如黄酮，异黄酮和查耳酮以及一些标准的抗氧化剂。使用计算机技术进一步分析了这些化合物的AChE抑制（AChEI）活性，即药效团作图，定量构效关系（QSAR）分析和分子对接研究。我们还比较了这些化合物的AChE抑制和自由基清除抗氧化活性。这些化合物的AChE抑制和抗氧化活性都高度依赖于其结构模式。但是，据观察，一般而言，
• Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20050059655A1

  公开（公告）日：2005-03-17

  The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (l) treating nephropathy.

  该发明描述了新颖的亚硝基化和/或亚硝酰化利尿化合物或其药用盐，以及包含至少一种亚硝基化和/或亚硝酰化利尿化合物的新型组合物，以及可选地至少一种一氧化氮供体和/或至少一种治疗剂。该发明还提供了包含该发明中至少一种利尿化合物的新型组合物和试剂盒，该利尿化合物可选择地亚硝基化和/或亚硝酰化，并且可选地至少一种一氧化氮供体化合物和/或至少一种治疗剂。该发明还提供了用于(a)治疗由于过多水分和/或电解贮留引起的疾病；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；和(l)治疗肾病的方法。
• Nitric oxide enhancing diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20060189603A1

  公开（公告）日：2006-08-24

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。